Group 1 - The Ministry of Transport, Ministry of Finance, and Ministry of Natural Resources have issued a plan to complete the construction and renovation of 300,000 kilometers of rural roads by 2027, aiming to establish a convenient and efficient rural road network [1] - The plan includes implementing 300,000 kilometers of repair and maintenance projects, maintaining a good road condition rate of over 70%, and carrying out safety protection projects on 150,000 kilometers of roads [1] - The initiative aims to enhance rural transportation services and support the vision of a well-structured, high-quality rural transportation system by 2035 [1] Group 2 - U.S. stock markets saw an overall increase, with the Dow Jones rising by 81.38 points (0.19%) and the Nasdaq increasing by 252.87 points (1.21%) [2] - Notable stock movements included Apple rising by 5% due to anticipated investments in U.S. manufacturing, and McDonald's gaining over 3% following better-than-expected earnings [2] - Many popular Chinese concept stocks also saw gains, with Alibaba up over 3% and NIO increasing by over 2% [2] Group 3 - The State Grid reported a record high electricity load for three consecutive days, reaching a maximum load of 1.233 billion kilowatts, an increase of 53 million kilowatts compared to last year's peak [3] - The electricity load is expected to remain above 1.2 billion kilowatts, with a potential decrease anticipated due to upcoming rainfall and cooler temperatures [3] Group 4 - The Hong Kong Monetary Authority intervened in the currency market, buying HKD 8.439 billion after the Hong Kong dollar hit the weak end of its trading band [4] - This action is part of the linked exchange rate system, where the HKMA sells USD and buys HKD to stabilize the currency [4] Group 5 - The China Photovoltaic Industry Association is soliciting opinions on the draft amendment to the Price Law, focusing on price behavior norms and regulatory mechanisms [5] - This initiative aims to reflect the demands of the photovoltaic industry and gather feedback for potential modifications [5] Group 6 - Guangnan Group's subsidiary successfully acquired land use rights in Foshan for RMB 56.16 million, expanding its meat industry chain [6] Group 7 - Caocao Travel is exploring the tokenization of real-world assets and stablecoin payments through a strategic partnership with a licensed financial institution in Hong Kong [7][8] Group 8 - Lianzhong is integrating AI technology into traditional board games, collaborating with tech companies to enhance gaming experiences [9] Group 9 - China National Pharmaceutical Group's self-developed drug TQ05105 has been included in the breakthrough therapy designation program for chronic graft-versus-host disease treatment [10] Group 10 - China Nuclear Technology expects a mid-year profit increase of no less than 15% compared to the previous year [11] Group 11 - Hengrui Medicine's product received orphan drug designation from the FDA, which may provide regulatory advantages in the U.S. market [12] Group 12 - Huaxian Optoelectronics anticipates a significant profit increase of at least 600% for the first half of 2025 [13] Group 13 - New World Development expects a mid-year profit of no less than HKD 800 million, a substantial increase from the previous year's HKD 75.4 million [14] Group 14 - Xinwei Medical expects to achieve a net profit of at least RMB 40 million in the first half of 2025, marking a turnaround from losses [15] Group 15 - Zhiyu Technology anticipates a mid-year profit increase of approximately 108.9% to 126.7% [16] Group 16 - Ningmeng Media expects to achieve a net profit of approximately RMB 10 million to 12 million in the first half of 2025, reversing previous losses [17] Group 17 - Weixin Jinke anticipates a significant profit increase of no less than RMB 200 million for the first half of 2025, reflecting a growth of at least 65% [18] Group 18 - Uni-President China reported a 33.24% increase in shareholder profit to RMB 1.287 billion for the mid-year period [19] Group 19 - BeiGene reported a net profit of USD 94.32 million for the second quarter, marking a turnaround from a loss of USD 120 million in the previous year [20] Group 20 - Maifushi expects to achieve a net profit of approximately RMB 31.8 million to 41 million in the first half of 2025, reversing a significant loss from the previous year [21]

Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for the combination of injection Rituximab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group's self-developed drug TQ05105 (JAK/ROCK inhibitor) has been included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanli Kang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.20 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD for the second quarter, returning to profitability year-on-year [1] - Sun Hung Kai Properties (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weixin Jinke (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - ZhiZi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - China Star Optoelectronics (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company for the first half of the year [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]

Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for the combination of injection Rituximab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group (01177) has its self-developed drug TQ05105 (JAK/ROCK inhibitor) included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanli Kang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.2 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD in the second quarter, returning to profitability year-on-year [1] - New World Development Company (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weixin Jinkao (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - ZhiZi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - Huaxian Optoelectronics (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]

Performance Highlights - BeiGene (06160.HK) reported a revenue of 17.518 billion yuan for the first half of the year, a year-on-year increase of 46%; product revenue was 17.36 billion yuan, up 45.8%; net profit was 450 million yuan, turning from loss to profit [2] - Uni-President China (00220.HK) achieved approximately 17.087 billion yuan in revenue for the first half, a year-on-year increase of 10.6%; net profit was about 1.287 billion yuan, up 33.2% [2] - Zhiyu City Technology (09911.HK) announced a positive profit forecast, expecting mid-term revenue of approximately 3.135 to 3.215 billion yuan, a year-on-year increase of about 38.0% to 41.5%; net profit is expected to be around 470 to 510 million yuan, a year-on-year growth of approximately 108.9% to 126.7% [2] Earnings Forecasts - New World Development Company (00086.HK) expects mid-term net profit to increase to no less than 800 million HKD year-on-year [3] - Weizhi Jinkou (02003.HK) anticipates mid-term net profit exceeding 200 million HKD, a significant increase year-on-year [3] - Wing Chan Industrial (01596.HK) forecasts mid-term net profit of approximately 48.7 million HKD, turning from loss to profit [3] - Huaxian Optoelectronics (00334.HK) expects mid-term net profit to exceed 48.8 million HKD, a year-on-year increase of over 600% [3] - Maifushi (02556.HK) predicts mid-term net profit of approximately 31.8 to 41 million HKD, turning from loss to profit [4] - Xinwei Medical-B (06609.HK) expects mid-term net profit to exceed 40 million HKD, turning from loss to profit [5] - China Nuclear Technology (00611.HK) anticipates mid-term net profit growth of over 15% [6] Earnings Warnings - Hongxing Printing Group (00450.HK) expects mid-term net loss of approximately 49 million HKD, a significant increase year-on-year [7] - Zhongyu Land (01224.HK) forecasts mid-term net loss of approximately 40 million HKD, turning from profit to loss [7] - Beihai Group (00701.HK) anticipates mid-term net loss of 36 to 40 million HKD [8] Real Estate Sales Data - China Overseas Development (00688.HK) reported cumulative contract property sales of approximately 132 billion yuan for the first seven months, a year-on-year decrease of 18.3% [9] - Yuexiu Property (00123.HK) achieved cumulative contract sales of approximately 67.506 billion yuan for the first seven months, a year-on-year increase of about 11.7% [9] - Poly Property Group (00119.HK) reported contract sales of approximately 29.5 billion yuan for the first seven months, a year-on-year decrease of 13.49% [10] - China Overseas Hongyang Group (00081.HK) reported cumulative contract sales of 18.649 billion yuan for the first seven months, a year-on-year decrease of 12.2% [10] - Jindi Commercial Real Estate (00535.HK) reported cumulative contract sales of approximately 6.98 billion yuan for the first seven months, a year-on-year decrease of 37.37% [10] - Agile Group (03383.HK) reported pre-sale amount of approximately 5.69 billion yuan for the first seven months [11] - Hongyang Real Estate (01996.HK) reported cumulative contract sales of 3.208 billion yuan for the first seven months, a year-on-year decrease of 41.6% [12] - Zhengrong Real Estate (06158.HK) reported cumulative contract sales of approximately 2.701 billion yuan for the first seven months, a year-on-year decrease of 30.6% [12] - Jingrui Holdings (01862.HK) reported cumulative contract sales of approximately 571 million yuan for the first seven months, a year-on-year decrease of 52.54% [13] Company News - CITIC Securities (06030.HK) reported that its subsidiary, Huaxia Fund, achieved revenue of 4.258 billion yuan and net profit of 1.123 billion yuan in the first half, with assets under management totaling 285.1237 billion yuan [14] - Xinyi International (00732.HK) reported a cumulative operating revenue of approximately 9.566 billion HKD for the first seven months, a year-on-year decrease of about 5.3% [15] - Heng Rui Pharmaceutical (01276.HK) received orphan drug designation from the US FDA for its injection of Rikan Trastuzumab combined with Adebali for gastric cancer or gastroesophageal junction adenocarcinoma indications [15] - Fuhong Hanlin (02696.HK) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanlikang® for active renal glomerulonephritis in China [15] - China Biopharmaceutical (01177.HK) announced that its self-developed TQ05105 (JAK/ROCK inhibitor) has been included in the breakthrough therapy designation program for the treatment of chronic graft-versus-host disease [15] Buyback Activities - HSBC Holdings (00005.HK) repurchased approximately 1.65 billion HKD worth of about 1.714 million shares at a price of 95.8 to 96.75 HKD [16] - Hang Seng Bank (00011.HK) spent approximately 22.6347 million HKD to repurchase 200,000 shares at a price of 112.8 to 113.6 HKD [17] - Yum China (09987.HK) repurchased approximately 6.264 million HKD worth of 16,800 shares at a price of 369.8 to 376 HKD [17]

Core Viewpoint - New Hong Ji Company (00086) expects a significant increase in shareholder profit for the six months ending June 30, 2025, projected to be no less than 800 million HKD, compared to 75.4 million HKD for the same period ending June 30, 2024 [1] Summary by Relevant Categories Financial Performance - The anticipated profit increase is primarily driven by higher investment income from the company's investment management business [1] - The profit from the company's credit business is expected to decrease, partially offsetting the gains from the investment management sector [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對 因本公佈全部 或任何部 分 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （ 於香港註冊成立之有限公司 ） （股份代號：86） 1 股東及潛在投資者在買賣本公司證券時，務請審慎行事。 代表 董事會 新鴻基有限公司 執行董事 Brendan James McGraw 香港，2025年8月6日 於本公佈日期，董事會成員包括： 執行董事： 正面盈利預告 本公佈乃新鴻基有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香 港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09(2)(a)條及香港法例 第 571 章《證券及期貨條例》第 XIVA 部項下之內幕消息條文（定義見上市規 則）而作出。 本公司董事會（「董事會」）謹此通知本公司股東（「股東」）及潛在投資者，根據 管理層目前可獲得之資料及對本集團截至2025年6月30日止六個月之最新未經審 核綜合管理賬目(「管理賬目」）作出的初步審閱及評估，預計截至2025年6月30日 止六個月本公司股東應佔溢利將不低於8 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 新鴻基有限公司 | | | | 呈交日期: | 2025年8月4日 | | | | I. 法定/註冊股本變動 不適用 | | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00086 | 說明 | | 普通股 | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,964,958,493 | | 0 | | 1,964,958,493 | | 增加 / ...

Core Viewpoint - The company has demonstrated strong performance across its three core business lines—credit, investment management, and fund management—capitalizing on structural opportunities in the market, leading to significant stock price appreciation and recognition in the investment community [1][2][4]. Group 1: Market Performance - The Hang Seng Index has rebounded from a low of approximately 18,600 points, achieving a year-to-date increase of 19.07%, with a total fluctuation of nearly 30% between its lowest and highest points [1]. - The company's stock price has risen approximately 30% year-to-date, aligning with structural opportunities in the Hong Kong stock market and global capital allocation trends [1]. Group 2: Investment Management - The investment management segment has shown resilience, with alternative investments making up 74.2% of the segment by the end of 2024, indicating a strong focus on high-quality investment opportunities [1]. - The company is expected to realize value in both the Hong Kong and U.S. stock markets by 2025, reflecting its strategic positioning [1]. Group 3: Fund Management - The total assets under management in the fund management business reached a record of $2 billion in 2024, representing a 109.3% increase, which contributed to a 191.7% year-on-year revenue growth to HKD 49 million [4]. - The company's hedge fund, SHK Latitude Alpha, received a nomination for the HFM Asia-Pacific Performance Awards, highlighting its strong performance metrics and enhancing investor confidence [5]. Group 4: Credit Business - The credit business has been a stable revenue source, with the company successfully managing a $100 million residential mortgage loan portfolio and recently being appointed to manage a second $70 million portfolio [6]. - The company has leveraged insights into the real estate sector's challenges to expand its credit services, allowing developers to focus on project sales and development [6]. Group 5: Strategic Investments - The investment in Jefferson Capital, a leader in U.S. distressed consumer debt management, showcases the company's ability to identify opportunities in the credit market, with Jefferson Capital set to go public in June 2025 [3]. - The company's strategic investments reflect a deep understanding of the credit industry and an international perspective, enabling it to discover undervalued companies [3].

Financial Performance - The company reported a profit attributable to shareholders of HK$377.7 million in 2024, a significant turnaround from a loss of HK$471.4 million in 2023[28]. - The return on equity and return on assets increased to 1.8% and 1.5%, respectively, compared to -2.2% and -0.5% in 2023[28]. - Total revenue decreased by 3.9% to HKD 3,762.0 million[40]. - Revenue for 2024 was HKD 3,762.0 million, a decrease of 3.9% from HKD 3,916.6 million in 2023[48]. - Pre-tax profit increased significantly to HKD 861.3 million in 2024, up 1024.4% from HKD 76.6 million in 2023[50]. - Basic earnings per share for 2024 were HKD 19.3 cents, recovering from a loss of HKD 24.1 cents in 2023[50]. - Total investment management revenue reached HKD 394.4 million, a significant recovery from a loss of HKD 332.0 million in 2023[33]. - The pre-tax profit from consumer finance business was HKD 807.3 million, down from HKD 979.5 million in 2023, impacted by a one-time foreign exchange loss of HKD 46.1 million[34]. - The company achieved a pre-tax profit margin increase of 1,024.4%, amounting to HKD 861.3 million[40]. Asset Management - Total assets of the group amounted to approximately HKD 37.3 billion as of December 31, 2024[8]. - Total assets under management reached a record of $2.0 billion, more than doubling from 2023[25]. - The total assets under management reached $2,018 million by the end of 2024, up from $964 million in 2023, reflecting a significant organic growth driven by strong cash inflows and good market performance across almost all strategies[124]. - The composition of assets under management showed a decrease in the company's capital from 37.2% in 2023 to 20.1% in 2024, while external investor capital increased from 62.8% to 79.9%[130]. - Revenue from fees increased by 55.6% year-on-year to $56.5 million in 2024, driven by the significant expansion of assets under management[132]. Investment Strategies - The investment management division has become a significant source of excess returns for the group in the medium to long term[18]. - The company is focusing on alternative investment strategies to capture market misalignments and generate favorable returns[20]. - The alternative investment portfolio generated a return of 2.6%, with hedge fund returns at 10.6% and private equity returns at 1.1%[75]. - The company is leveraging its expertise and resources to transform into a leading alternative investment platform[24]. - The company plans to enhance its fund management platform through new partnerships and expanded distribution networks[136]. Credit and Loan Business - The credit business offers a diversified loan portfolio, including consumer finance and mortgage loans, providing stable returns[15]. - The company launched the SIM credit card in 2023 to meet the demand for quick-response credit solutions[16]. - The mortgage lending division introduced asset management services for residential mortgage portfolios in 2024[17]. - The credit business achieved a pre-tax profit of HKD 846.8 million, a decrease of 4.5% from HKD 886.3 million in 2023[53]. - The total loan balance in Hong Kong reached HKD 9,199.4 million, reflecting a slight increase of 0.8% compared to HKD 9,123.7 million in 2023[63]. Risk Management - The company maintains a diversified funding source to manage market risks effectively[170]. - Key risks identified include strategic risk, credit risk, market risk, liquidity risk, and operational risk, each with specific mitigation measures[170]. - The risk management framework is based on a "three lines of defense" model, ensuring effective oversight and internal controls[161]. - The company has implemented additional monitoring measures, resulting in an overall reduction in risk levels[168]. - Continuous improvement of the electronic risk management system has enhanced data collection and reporting efficiency[168]. Corporate Governance - The board of directors emphasizes high standards of corporate governance to enhance shareholder value[173]. - The company has established a strong compliance culture and has implemented internal policies to regulate its activities[154]. - The board consists of eight male directors and two female directors, meeting gender diversity requirements[192]. - The company has adopted a board diversity policy since September 1, 2013, to improve the overall skills and experience of the board[189]. - The nomination committee is responsible for ensuring a balanced perspective in terms of skills, experience, and diversity in the board composition[196]. Employee and Operational Efficiency - Employee headcount decreased to 978 from 1,087 in 2023, with total employee costs down to HKD 593.2 million from HKD 625.8 million[151]. - The company emphasizes employee well-being, competitive salaries, and career development to attract and retain top talent[153]. - The company plans to enhance operational efficiency by integrating AI tools and streamlining business processes[76]. - The implementation of a scalable and efficient customer relationship management (CRM) system has improved communication with clients and streamlined relationship management processes[121].

新鸿基公司扭亏背后：业务协同发力驱动盈利韧性增长 看 好另类投资平台价值持续兑现 今年以来，恒指从最低19600点附近开启反弹行情，不断创出新高。年初至3月17日，恒生指数和恒生科技指数涨 幅分别达20.37%和31.44%，在全球各类资产中"遥遥领先"。 在当前港股市场强势反弹环境下，"哑铃策略"可以通过两端资产的平衡，实现风险分散和收益最大化。"哑铃"的 一边是产业趋势引领的科技成长类资产，另一边则是稳定的高股息资产。尤其在市场不确定凸显时，高股息资产不仅 能够提供稳定的分红收益，还能在市场下跌时起到缓冲作用。 由此来看，通过"哑铃策略"实现攻守平衡，或是投资者在港股进行资产配置的最优解。新鸿基公司(00086)作为优 质的高股息标的，可以用"确定性分红"对抗波动，自2024年至今，新鸿基公司股价涨幅接近35%，涨势喜人，可见投 资者对其认可。 3月20日，新鸿基公司发布2024年度业绩。期内，公司总收益为38.43亿元(单位：港元，下同)，股东应占溢利为 3.78亿元，同比扭亏为盈。此外，公司宣布派发第二次中期股息每股14港仙。连同中期股息每股12港仙，每股股息总 额为26港仙，按3月21日的收盘价算， ...